" class="no-js "lang="en-US"> Anne-Marie Baird - Medtech Alert
Sunday, August 17, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Anne-Marie Baird

Anne-Marie Baird

About Anne-Marie Baird

Experienced cancer molecular biologist with research interests in inflammation and immune
mediators, metastatic cascade, drug resistance and disease biomarkers. Dedicated patient advocate at a
national and European level, working to influence policy change and inspire patient driven research.

Related Story

Diseases

 CHMP Recommends EU Approval of Roche’s Tecentriq as Adjuvant Treatment for a Subset of People with Early-stage Non-small Cell Lung Cancer | Pharmtech Focus

CHMP Recommends EU Approval of Roche’s Tecentriq as Adjuvant Treatment for a Subset of People with Early-stage Non-small Cell Lung Cancer

April 25 2022

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee […]